Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

CAR-T Cell Therapies From the Transfusion Medicine Perspective.

Fesnak A, Lin C, Siegel DL, Maus MV.

Transfus Med Rev. 2016 Jul;30(3):139-45. doi: 10.1016/j.tmrv.2016.03.001. Epub 2016 Mar 28. Review.

2.

Adoptive therapy with CAR redirected T cells for hematological malignancies.

Li S, Yang Z, Shen J, Shan J, Qian C.

Sci China Life Sci. 2016 Apr;59(4):370-8. doi: 10.1007/s11427-016-5036-3. Epub 2016 Mar 22. Review.

PMID:
27009302
3.

Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.

Jakobczyk H, Sciortino F, Chevance S, Gauffre F, Troadec MB.

Int J Pharm. 2017 Nov 5;532(2):813-824. doi: 10.1016/j.ijpharm.2017.07.075. Epub 2017 Jul 29.

4.

Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.

Zhang BL, Qin DY, Mo ZM, Li Y, Wei W, Wang YS, Wang W, Wei YQ.

Sci China Life Sci. 2016 Apr;59(4):340-8. doi: 10.1007/s11427-016-5027-4. Epub 2016 Mar 11. Review.

PMID:
26965525
5.

Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.

Fujiwara H.

Int J Hematol. 2014 Feb;99(2):123-31. doi: 10.1007/s12185-013-1493-7. Epub 2013 Dec 19. Review.

PMID:
24352938
6.

Toxicities of chimeric antigen receptor T cells: recognition and management.

Brudno JN, Kochenderfer JN.

Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20. Review.

7.

[Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review].

Cheng X, Wang YJ, Feng S, Wu YY, Yang TH, Lai X.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Apr;26(2):626-630. doi: 10.7534/j.issn.1009-2137.2018.02.054. Review. Chinese.

PMID:
29665944
8.

[Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].

Zhou SY, Shi YK.

Zhonghua Zhong Liu Za Zhi. 2018 Jul 23;40(7):490-492. doi: 10.3760/cma.j.issn.0253-3766.2018.07.002. Chinese.

PMID:
30060355
9.

[CAR T-cell therapy: Balance of efficacy and safety].

Kulemzin SV, Kuznetsova VV, Mamonkin M, Taranin AV, Gorchakov AA.

Mol Biol (Mosk). 2017 Mar-Apr;51(2):274-287. doi: 10.7868/S0026898417020148. Review. Russian.

10.

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Park JH, Geyer MB, Brentjens RJ.

Blood. 2016 Jun 30;127(26):3312-20. doi: 10.1182/blood-2016-02-629063. Epub 2016 May 20. Review.

11.

Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.

Allegra A, Innao V, Gerace D, Vaddinelli D, Musolino C.

Blood Cells Mol Dis. 2016 Nov;62:49-63. doi: 10.1016/j.bcmd.2016.11.001. Epub 2016 Nov 10. Review.

PMID:
27865176
12.

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.

Gill S, June CH.

Immunol Rev. 2015 Jan;263(1):68-89. doi: 10.1111/imr.12243. Review.

PMID:
25510272
13.

Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.

Badieyan ZS, Hoseini SS.

Arch Immunol Ther Exp (Warsz). 2018 Aug;66(4):283-288. doi: 10.1007/s00005-018-0507-9. Epub 2018 Feb 9. Review.

PMID:
29427174
14.

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.

Grigor EJM, Fergusson DA, Haggar F, Kekre N, Atkins H, Shorr R, Holt RA, Hutton B, Ramsay T, Seftel M, Jonker D, Daugaard M, Thavorn K, Presseau J, Lalu MM.

BMJ Open. 2017 Dec 29;7(12):e019321. doi: 10.1136/bmjopen-2017-019321.

15.
16.

Current status of chimeric antigen receptor therapy for haematological malignancies.

Maude S, Barrett DM.

Br J Haematol. 2016 Jan;172(1):11-22. doi: 10.1111/bjh.13792. Epub 2015 Nov 12. Review.

PMID:
26560054
17.

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.

Liu J, Zhong JF, Zhang X, Zhang C.

J Hematol Oncol. 2017 Jan 31;10(1):35. doi: 10.1186/s13045-017-0405-3. Review.

18.

Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.

Yoon DH, Osborn MJ, Tolar J, Kim CJ.

Int J Mol Sci. 2018 Jan 24;19(2). pii: E340. doi: 10.3390/ijms19020340. Review.

19.

CD19 chimeric antigen receptor T cell therapy for haematological malignancies.

Ghorashian S, Pule M, Amrolia P.

Br J Haematol. 2015 May;169(4):463-78. doi: 10.1111/bjh.13340. Epub 2015 Mar 5. Review.

PMID:
25753571
20.

Chimeric Antigen Receptor T Cells in Hematologic Malignancies.

Shank BR, Do B, Sevin A, Chen SE, Neelapu SS, Horowitz SB.

Pharmacotherapy. 2017 Mar;37(3):334-345. doi: 10.1002/phar.1900. Epub 2017 Feb 22. Review.

PMID:
28079265

Supplemental Content

Support Center